WFA
CYTK icon

Wipfli Financial Advisors’s Cytokinetics CYTK Stock Holding History

Wipfli Financial Advisors’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		$45K Buy
+935
New +$45K ﹤0.01% 1124

Other funds holding CYTK

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Wipfli Financial Advisors's CYTK Position: Q3 2022 in Review

Wipfli Financial Advisors opened a new position in Cytokinetics (CYTK) in Q3 2022: 935 shares worth $45K. The stake represents ﹤0.01% of the portfolio and ranks #1124 among its holdings.

277 funds tracked by Wall St. Rank hold CYTK as of Q3 2022.

  • Wipfli Financial Advisors held 935 shares of Cytokinetics worth $45K as of Q3 2022.
  • Cytokinetics was a new Wipfli Financial Advisors position in Q3 2022.
  • Cytokinetics made up ﹤0.01% of Wipfli Financial Advisors's portfolio in Q3 2022, its #1124 holding.
  • 277 funds tracked by Wall St. Rank held Cytokinetics as of Q3 2022.

Based on Wipfli Financial Advisors's 13F filing for Q3 2022, filed 26 Oct 2022.